Phase III SCORED trial of Zynquista shows improvements in patients with type 2 diabetes and chronic kidney disease.- Lexicon Pharma

Treatment with sotagliflozin resulted in a significant reduction in major adverse cardiovascular events (MACE) of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in the entire cohort as compared to placebo. This analysis also evaluated the effect of sotagliflozin on MACE in prespecified subgroups of patients with cardiovascular disease (CVD; n=5,144) and without CVD (n=5,440) at baseline. The analysis showed consistent reductions in MACE in both subgroups with a relative risk reduction in MACE of 21% in patients with and 26% in patients without CVD, in each case compared to placebo. The analysis demonstrates that in addition to reducing heart failure events, sotagliflozin reduced MACE events. The lower rates of MACE, notably including reductions in both heart attack and stroke, were consistent in patients with and without cardiovascular disease at baseline.

The data were presented at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22). The presentation was entitled, “Sotagliflozin Significantly Reduces Cardiovascular Death, Myocardial Infarction, and Stroke in the SCORED Trial”.